Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 157

Similar articles for PubMed (Select 23393027)

1.

Studies on abacavir-induced hypersensitivity reaction: a successful example of translation of pharmacogenetics to personalized medicine.

Guo Y, Shi L, Hong H, Su Z, Fuscoe J, Ning B.

Sci China Life Sci. 2013 Feb;56(2):119-24. doi: 10.1007/s11427-013-4438-8. Epub 2013 Feb 8. Review. Erratum in: Sci China Life Sci. 2013 Mar;56(3):292.

PMID:
23393027
2.

Successful translation of pharmacogenetics into the clinic: the abacavir example.

Phillips E, Mallal S.

Mol Diagn Ther. 2009;13(1):1-9. doi: 10.2165/01250444-200913010-00001. Review.

PMID:
19351209
3.

Abacavir hypersensitivity reaction: an update.

Hughes CA, Foisy MM, Dewhurst N, Higgins N, Robinson L, Kelly DV, Lechelt KE.

Ann Pharmacother. 2008 Mar;42(3):387-96. doi: 10.1345/aph.1K522. Epub 2008 Feb 26. Review.

PMID:
18303141
4.

Abacavir pharmacogenetics--from initial reports to standard of care.

Martin MA, Kroetz DL.

Pharmacotherapy. 2013 Jul;33(7):765-75. doi: 10.1002/phar.1278. Epub 2013 May 3. Review.

5.

A sensitive and rapid alternative to HLA typing as a genetic screening test for abacavir hypersensitivity syndrome.

Martin AM, Krueger R, Almeida CA, Nolan D, Phillips E, Mallal S.

Pharmacogenet Genomics. 2006 May;16(5):353-7.

PMID:
16609367
6.

Successful implementation of a national HLA-B*5701 genetic testing service in Canada.

Lalonde RG, Thomas R, Rachlis A, Gill MJ, Roger M, Angel JB, Smith G, Higgins N, Trottier B.

Tissue Antigens. 2010 Jan;75(1):12-8. doi: 10.1111/j.1399-0039.2009.01383.x. Epub 2009 Oct 15.

PMID:
19843279
7.

HLA-B*5701 screening for hypersensitivity to abacavir.

Mallal S, Phillips E, Carosi G, Molina JM, Workman C, Tomazic J, Jägel-Guedes E, Rugina S, Kozyrev O, Cid JF, Hay P, Nolan D, Hughes S, Hughes A, Ryan S, Fitch N, Thorborn D, Benbow A; PREDICT-1 Study Team.

N Engl J Med. 2008 Feb 7;358(6):568-79. doi: 10.1056/NEJMoa0706135.

8.

High sensitivity of human leukocyte antigen-b*5701 as a marker for immunologically confirmed abacavir hypersensitivity in white and black patients.

Saag M, Balu R, Phillips E, Brachman P, Martorell C, Burman W, Stancil B, Mosteller M, Brothers C, Wannamaker P, Hughes A, Sutherland-Phillips D, Mallal S, Shaefer M; Study of Hypersensitivity to Abacavir and Pharmacogenetic Evaluation Study Team.

Clin Infect Dis. 2008 Apr 1;46(7):1111-8. doi: 10.1086/529382.

9.

[Prospective validation of a pharmacogenetic test: the PREDICT-1 study].

Muñoz de Benito RM, Arribas López JR.

Enferm Infecc Microbiol Clin. 2008 May;26 Suppl 6:40-4. Spanish. Erratum in: Enferm Infecc Microbiol Clin. 2008 Oct;26(8):536.

PMID:
18680695
10.

Prospective HLA-B*5701 screening and abacavir hypersensitivity: a single centre experience.

Waters LJ, Mandalia S, Gazzard B, Nelson M.

AIDS. 2007 Nov 30;21(18):2533-4.

PMID:
18025891
11.

Distribution of HLA-B alleles in a Ugandan HIV-infected adult population: NORA pharmacogenetic substudy of DART.

Munderi P, Snowden WB, Walker AS, Kityo C, Mosteller M, Kabuye G, Thoofer NK, Ssali F, Gilks CF, Hughes AR; DART Trial Team.

Trop Med Int Health. 2011 Feb;16(2):200-4. doi: 10.1111/j.1365-3156.2010.02688.x. Epub 2010 Nov 23.

12.

Association between presence of HLA-B*5701, HLA-DR7, and HLA-DQ3 and hypersensitivity to HIV-1 reverse-transcriptase inhibitor abacavir.

Mallal S, Nolan D, Witt C, Masel G, Martin AM, Moore C, Sayer D, Castley A, Mamotte C, Maxwell D, James I, Christiansen FT.

Lancet. 2002 Mar 2;359(9308):727-32.

PMID:
11888582
13.

Human leukocyte antigen (HLA) and pharmacogenetics: screening for HLA-B*57:01 among human immunodeficiency virus-positive patients from southern Alberta.

Berka N, Gill JM, Liacini A, O'Bryan T, Khan FM.

Hum Immunol. 2012 Feb;73(2):164-7. doi: 10.1016/j.humimm.2011.12.002. Epub 2011 Dec 8.

PMID:
22197535
14.

Economic efficiency of genetic screening to inform the use of abacavir sulfate in the treatment of HIV.

Kauf TL, Farkouh RA, Earnshaw SR, Watson ME, Maroudas P, Chambers MG.

Pharmacoeconomics. 2010;28(11):1025-39. doi: 10.2165/11535540-000000000-00000.

PMID:
20575592
15.

HLA-B*5701 genetic screening prior to abacavir prescription in Georgia.

Dvali N, Chkhartishvili N, Sharvadze L, Karchava M, Tsertsvadze T.

Georgian Med News. 2010 Dec;(189):16-20.

PMID:
21252404
16.

The cost-effectiveness of HLA-B*5701 genetic screening to guide initial antiretroviral therapy for HIV.

Schackman BR, Scott CA, Walensky RP, Losina E, Freedberg KA, Sax PE.

AIDS. 2008 Oct 1;22(15):2025-33. doi: 10.1097/QAD.0b013e3283103ce6.

17.

Cost-effectiveness analysis of HLA-B*5701 typing in the prevention of hypersensitivity to abacavir in HIV+ patients in Spain.

Nieves Calatrava D, Calle-Martín Ode L, Iribarren-Loyarte JA, Rivero-Román A, García-Bujalance L, Pérez-Escolano I, Brosa-Riestra M.

Enferm Infecc Microbiol Clin. 2010 Nov;28(9):590-5. doi: 10.1016/j.eimc.2009.09.010. Epub 2010 Feb 9. Erratum in: Enferm Infecc Microbiol Clin. 2012 Jun;30(6):356.

PMID:
20144493
18.

Cost-effectiveness analysis of HLA B*5701 genotyping in preventing abacavir hypersensitivity.

Hughes DA, Vilar FJ, Ward CC, Alfirevic A, Park BK, Pirmohamed M.

Pharmacogenetics. 2004 Jun;14(6):335-42.

PMID:
15247625
19.

A simple screening approach to reduce B*5701-associated abacavir hypersensitivity on the basis of sequence variation in HIV reverse transcriptase.

Chui CK, Brumme ZL, Brumme CJ, Yip B, Phillips EJ, Montaner JS, Harrigan PR.

Clin Infect Dis. 2007 Jun 1;44(11):1503-8. Epub 2007 Apr 18.

20.

[HLA-B*5701 and abacavir hypersensitivity reaction].

Servonnet A, Leclercq E, Delacour H, Ceppa F.

Pathol Biol (Paris). 2010 Dec;58(6):e95-100. doi: 10.1016/j.patbio.2008.12.001. Epub 2009 Feb 24. French.

PMID:
19243901
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk